Kayla Reid

1.1k total citations
17 papers, 196 citations indexed

About

Kayla Reid is a scholar working on Oncology, Electrical and Electronic Engineering and Immunology. According to data from OpenAlex, Kayla Reid has authored 17 papers receiving a total of 196 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 5 papers in Electrical and Electronic Engineering and 4 papers in Immunology. Recurrent topics in Kayla Reid's work include CAR-T cell therapy research (17 papers), Integrated Circuits and Semiconductor Failure Analysis (3 papers) and Immune Cell Function and Interaction (3 papers). Kayla Reid is often cited by papers focused on CAR-T cell therapy research (17 papers), Integrated Circuits and Semiconductor Failure Analysis (3 papers) and Immune Cell Function and Interaction (3 papers). Kayla Reid collaborates with scholars based in United States, Netherlands and Canada. Kayla Reid's co-authors include Marco L. Davila, Frederick L. Locke, Kristen Spitler, Justin C. Boucher, Sae Bom Lee, Emiliano Roselli, Nhan Tu, Hiroshi Kotani, Yannick Bulliard and Bin Yu and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and The Journal of Immunology.

In The Last Decade

Kayla Reid

15 papers receiving 194 citations

Peers

Kayla Reid

ONCOL

IMMUN

GENET

Jinlong Xu China

Yue Tan China

Daniella Cook United States

Sara Silbert United States

Miriam Sánchez‐Escamilla Spain

Erica R. Vander Mause United States

Brianna Flynn United States

John Pineda United States

Ruud Ruiter Netherlands

Nathaniel Dasyam New Zealand

Jinlong Xu China

Kayla Reid

139 ×0.8

ONCOL

37 ×0.6

42 ×0.8

IMMUN

51 ×1.0

GENET

41 ×0.8

Citations per year, relative to Kayla Reid Kayla Reid (= 1×) peers Jinlong Xu

Countries citing papers authored by Kayla Reid

Since Specialization

Citations

This map shows the geographic impact of Kayla Reid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kayla Reid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kayla Reid more than expected).

Fields of papers citing papers by Kayla Reid

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kayla Reid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kayla Reid. The network helps show where Kayla Reid may publish in the future.

Co-authorship network of co-authors of Kayla Reid

This figure shows the co-authorship network connecting the top 25 collaborators of Kayla Reid. A scholar is included among the top collaborators of Kayla Reid based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kayla Reid. Kayla Reid is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Boucher, Justin C., Bishwas Shrestha, Mark B. Leick, et al.. (2023). Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Molecular Therapy — Oncolytics. 31. 100751–100751. 21 indexed citations

Bejanyan, Nelli, Hany Elmariah, Kayla Reid, et al.. (2023). Phase I Trial of Allogeneic Donor Gamma Delta T Cell Infusion Post-Hematopoietic Cell Transplantation, an Interim Safety Report. Blood. 142(Supplement 1). 4846–4846. 1 indexed citations

Ionescu, Filip, Bijal Shah, Meghan Menges, et al.. (2023). Cladribine and Cyclophosphamide Lymphodepletion Prior to Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma. Blood. 142(Supplement 1). 4884–4884.

Locke, Frederick L., Michael D. Jain, Joel G. Turner, et al.. (2023). CD19 Intron Retention Is Mechanism of CAR-T Treatment Resistance in Non-Hodgkin Lymphoma. Blood. 142(Supplement 1). 3506–3506. 1 indexed citations

Hansen, Doris K., Lauren C. Peres, Kayla Reid, et al.. (2023). A Pro-Inflammatory State and Peak Cytokines Are Associated with Toxicity and Early Responses in Real-World Multiple Myeloma Patients Treated with Idecabtagene Vicleucel. Blood. 142(Supplement 1). 1004–1004. 2 indexed citations

Jain, Michael D., Bachisio Ziccheddu, Caroline A. Coughlin, et al.. (2022). Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood. 140(5). 491–503. 36 indexed citations

Li, Gongbo, et al.. (2022). CD3 engagement as a new strategy for allogeneic “off-the-shelf” T cell therapy. Molecular Therapy — Oncolytics. 24. 887–896. 3 indexed citations

Boucher, Justin C., Bishwas Shrestha, Mark B. Leick, et al.. (2022). Bispecific CD33/CD123 Targeted Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia. Blood. 140(Supplement 1). 10275–10276. 8 indexed citations

Mokhtari, Sepideh, Jeffrey A. Silverman, Kayla Reid, et al.. (2021). Transverse myelitis after anti‐CD19 directed CAR T cell therapy for relapsed large B cell lymphoma. SHILAP Revista de lepidopterología. 3(1). 223–227. 10 indexed citations

10.

Gaballa, Sameh, Julio C. Chávez, Michael D. Jain, et al.. (2021). Concurrent Monitoring of Peripheral Blood Circulating Tumor DNA and Circulating Tumor Cells in Relapsed/Refractory Follicular Lymphoma Patients Post Axicabtagene Ciloleucel, a Single Center Experience. Blood. 138(Supplement 1). 2397–2397.

11.

Roselli, Emiliano, Justin C. Boucher, Gongbo Li, et al.. (2021). 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells. Journal for ImmunoTherapy of Cancer. 9(10). e003354–e003354. 85 indexed citations

12.

Jain, Michael D., Bachisio Ziccheddu, Caroline A. Coughlin, et al.. (2021). Genomic Drivers of Large B-Cell Lymphoma Resistance to CD19 CAR-T Therapy. Blood. 138(Supplement 1). 42–42. 7 indexed citations

13.

Roselli, Emiliano, Justin C. Boucher, Gongbo Li, et al.. (2021). 105 4–1BB and optimized CD28 co-stimulation enhances function of human mono- and bi-specific third-generation CAR T cells. SHILAP Revista de lepidopterología. A115–A116. 1 indexed citations

14.

Mirza, Abu‐Sayeef, Ambuj Kumar, Hamza Hashmi, et al.. (2020). Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma. Transplantation and Cellular Therapy. 27(3). 242.e1–242.e6. 7 indexed citations

15.

Boucher, Justin C., et al.. (2020). Optimization of CAR T cell co-stimulation reduces to MDSC suppression. The Journal of Immunology. 204(1_Supplement). 170.3–170.3. 2 indexed citations

16.

Jain, Michael D., Rawan Faramand, Verena Staedtke, et al.. (2019). The Lymphoma Tumor Microenvironment Influences Toxicity after CD19 CAR T Cell Therapy. Blood. 134(Supplement_1). 4105–4105. 4 indexed citations

17.

Boucher, Justin C., et al.. (2019). MDSC Suppression of CAR T Cells Can be Reduced By Targeted Signaling Disruption. Blood. 134(Supplement_1). 4438–4438. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact